STOCK TITAN

Shareholder in DNLI (NASDAQ: DNLI) plans 150,000-share stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A shareholder in DNLI has filed a notice of intent to sell 150,000 shares of common stock on the NASDAQ, with an aggregate market value of $3,324,060. The planned sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of February 3, 2026.

The shares were acquired on February 2, 2026 by exercising stock options under a registered plan, in three transactions for 22,042, 44,021, and 83,937 shares, all paid in cash. The filing notes that there were 146,661,833 shares of this class of stock outstanding.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for DNLI disclose?

The Form 144 shows a DNLI shareholder intends to sell 150,000 common shares on NASDAQ, valued at about $3,324,060. The shares were recently acquired by exercising stock options under a registered plan and will be sold through Morgan Stanley Smith Barney.

How many DNLI shares are planned to be sold under this Form 144?

The filing indicates a proposed sale of 150,000 DNLI common shares. These shares were obtained via recent stock option exercises and are planned for sale on the NASDAQ through Morgan Stanley Smith Barney, subject to Rule 144 resale conditions and market execution.

What is the aggregate market value of DNLI shares in this Form 144?

The proposed DNLI share sale has an indicated aggregate market value of about $3,324,060. This value is based on 150,000 common shares listed in the filing and reflects the approximate market pricing at the time the notice was prepared.

When were the DNLI shares in the Form 144 acquired and how?

The DNLI shares were acquired on February 2, 2026 through exercise of options under a registered plan. Three option exercises totaling 150,000 shares were completed, and the form specifies that payment for these exercises was made entirely in cash.

On which exchange will the DNLI Form 144 shares be sold?

The Form 144 states that the 150,000 DNLI common shares are intended to be sold on the NASDAQ stock market. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker handling the planned transaction for the shareholder.

How many DNLI shares are outstanding according to the Form 144?

The filing reports that there are 146,661,833 DNLI common shares outstanding. This figure provides context for the planned sale of 150,000 shares, indicating the relative size of the proposed transaction compared with the total shares currently in circulation.
Denali Therapeut

NASDAQ:DNLI

DNLI Rankings

DNLI Latest News

DNLI Latest SEC Filings

DNLI Stock Data

3.13B
140.31M
9.83%
96.25%
9.4%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO